The estimated Net Worth of Mark H Skolnick is at least $8.63 millió dollars as of 4 November 2009. Mark Skolnick owns over 192,000 units of Myriad Genetics stock worth over $893,520 and over the last 22 years Mark sold MYGN stock worth over $7,736,665.
Mark has made over 23 trades of the Myriad Genetics stock since 2005, according to the Form 4 filled with the SEC. Most recently Mark sold 192,000 units of MYGN stock worth $4,884,480 on 4 November 2009.
The largest trade Mark's ever made was selling 192,000 units of Myriad Genetics stock on 4 November 2009 worth over $4,884,480. On average, Mark trades about 12,439 units every 40 days since 2003. As of 4 November 2009 Mark still owns at least 34,000 units of Myriad Genetics stock.
You can see the complete history of Mark Skolnick stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is , , , , .
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum és Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: